HPRT Deficiency Coordinately Dysregulates Canonical Wnt and Presenilin-1 Signaling: A Neuro-Developmental Regulatory Role for a Housekeeping Gene?

We have used microarray-based methods of global gene expression together with quantitative PCR and Western blot analysis to identify dysregulation of genes and aberrant cellular processes in human fibroblasts and in SH-SY5Y neuroblastoma cells made HPRT-deficient by transduction with a retrovirus stably expressing an shRNA targeted against HPRT. Analysis of the microarray expression data by Gene ontology (GO) and Gene Set Enrichment Analysis (GSEA) as well as significant pathway analysis by GeneSpring GX10 and Panther Classification System reveal that HPRT deficiency is accompanied by aberrations in a variety of pathways known to regulate neurogenesis or to be implicated in neurodegenerative disease, including the canonical Wnt/β-catenin and the Alzheimer's disease/presenilin signaling pathways. Dysregulation of the Wnt/β-catenin pathway is confirmed by Western blot demonstration of cytosolic sequestration of β-catenin during in vitro differentiation of the SH-SY5Y cells toward the neuronal phenotype. We also demonstrate that two key transcription factor genes known to be regulated by Wnt signaling and to be vital for the generation and function of dopaminergic neurons; i.e., Lmx1a and Engrailed 1, are down-regulated in the HPRT knockdown SH-SY5Y cells. In addition to the Wnt signaling aberration, we found that expression of presenilin-1 shows severely aberrant expression in HPRT-deficient SH-SY5Y cells, reflected by marked deficiency of the 23 kDa C-terminal fragment of presenilin-1 in knockdown cells. Western blot analysis of primary fibroblast cultures from two LND patients also shows dysregulated presenilin-1 expression, including aberrant proteolytic processing of presenilin-1. These demonstrations of dysregulated Wnt signaling and presenilin-1 expression together with impaired expression of dopaminergic transcription factors reveal broad pleitropic neuro-regulatory defects played by HPRT expression and suggest new directions for investigating mechanisms of aberrant neurogenesis and neuropathology in LND and potential new targets for restoration of effective signaling in this neuro-developmental defect.

[1]  Randall T Moon,et al.  WNT and beta-catenin signalling: diseases and therapies. , 2004, Nature reviews. Genetics.

[2]  J. Rothstein,et al.  Oxidative stress and dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. , 2002, Brain research. Developmental brain research.

[3]  E. Arenas,et al.  Emerging roles of Wnts in the adult nervous system , 2010, Nature Reviews Neuroscience.

[4]  Yun Bai,et al.  Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease β-amyloid production , 2008, Journal of cellular and molecular medicine.

[5]  A. Takashima,et al.  Direct association of presenilin‐1 with β‐catenin , 1998 .

[6]  Giancarlo V. De Ferrari and,et al.  Wnt signaling function in Alzheimer’s disease , 2000, Brain Research Reviews.

[7]  Alan C. Evans,et al.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Castelo-Branco,et al.  GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. , 2004, Journal of cell science.

[9]  Hans Clevers,et al.  Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis , 1998, Nature.

[10]  D. Seiffert,et al.  γ-Secretase activity is not involved in presenilin-mediated regulation of β-catenin ☆ , 2002 .

[11]  G. Castelo-Branco,et al.  GSK-3β inhibition/β-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons , 2004, Journal of Cell Science.

[12]  Ernest Arenas,et al.  Function of Wnts in Dopaminergic Neuron Development , 2006, Neurodegenerative Diseases.

[13]  I. Hammel,et al.  Decelerated rate of dendrite outgrowth from dopaminergic neurons in primary cultures from brains of hypoxanthine phosphoribosyltransferase-deficient knockout mice , 2001, Neuroscience Letters.

[14]  R Sásik,et al.  Microarray truths and consequences. , 2004, Journal of molecular endocrinology.

[15]  H. Shibasaki,et al.  Presenilin 1 mediates retinoic acid‐induced differentiation of SH‐SY5Y cells through facilitation of Wnt signaling , 2003, Journal of neuroscience research.

[16]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[17]  L. Dauphinot,et al.  Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch-Nyhan disease pathogenesis. , 2009, Human molecular genetics.

[18]  Henry Yang,et al.  MicroRNA-125b Promotes Neuronal Differentiation in Human Cells by Repressing Multiple Targets , 2009, Molecular and Cellular Biology.

[19]  S. Krauss,et al.  A dynamic gradient of Wnt signaling controls initiation of neurogenesis in the mammalian cortex and cellular specification in the hippocampus. , 2007, Developmental biology.

[20]  H. Jinnah,et al.  Lesch–Nyhan disease and the basal ganglia , 2000, Brain Research Reviews.

[21]  H. Jinnah,et al.  Consequences of impaired purine recycling in dopaminergic neurons , 2008, Neuroscience.

[22]  B. Bloem,et al.  Delineation of the motor disorder of Lesch-Nyhan disease. , 2006, Brain : a journal of neurology.

[23]  W. Nyhan,et al.  An improved procedure for detection of hypoxanthine--guanine phosphoribosyl transferase heterozygotes. , 1982, Clinical chemistry.

[24]  B. Strooper,et al.  Presenilins and the intramembrane proteolysis of proteins: facts and fiction , 2001, Nature Cell Biology.

[25]  M. Mishkin,et al.  Differential effects of early hippocampal pathology on episodic and semantic memory. , 1997, Science.

[26]  M. Ernst,et al.  Presynaptic dopaminergic deficits in Lesch-Nyhan disease. , 1996, The New England journal of medicine.

[27]  Antonio Sanfilippo,et al.  Using the gene ontology to enrich biological pathways , 2009, Int. J. Comput. Biol. Drug Des..

[28]  Robert Howard,et al.  The dopaminergic basis of cognitive and motor performance in Alzheimer's disease , 2010, Neurobiology of Disease.

[29]  G. Bernardi,et al.  Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer's Disease Patients , 2009, Neuropsychopharmacology.

[30]  P. Kloetzel,et al.  Expression of Alzheimer’s Disease-associated Presenilin-1 Is Controlled by Proteolytic Degradation and Complex Formation* , 1998, The Journal of Biological Chemistry.

[31]  D. Small,et al.  Presenilins and the γ-secretase: still a complex problem , 2010, Molecular Brain.

[32]  K. Shannak,et al.  Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. , 1981, The New England journal of medicine.

[33]  O. Lindvall,et al.  Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. , 2008, The Journal of clinical investigation.

[34]  G. Invernici,et al.  Human neural stem cells: a model system for the study of Lesch-Nyhan disease neurological aspects. , 2010, Human molecular genetics.

[35]  J. Topczewski,et al.  The emerging role of Wnt/PCP signaling in organ formation. , 2009, Zebrafish.

[36]  Thomas Ragg,et al.  The RIN: an RNA integrity number for assigning integrity values to RNA measurements , 2006, BMC Molecular Biology.

[37]  Theodore Friedmann,et al.  Tissue-specific aberrations of gene expression in HPRT-deficient mice: functional complexity in a monogenic disease? , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  S. Takashima,et al.  Dopamine receptor upregulation in Lesch-Nyhan syndrome: a postmortem study. , 1999, Neuropediatrics.

[39]  P. Greengard,et al.  Evidence for phosphorylation and oligomeric assembly of presenilin 1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Björklund,et al.  Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells , 2009, Proceedings of the National Academy of Sciences.

[41]  William,et al.  The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00) , 2004, Biochemistry (Moscow).

[42]  R. Tanzi,et al.  Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. , 1997, Science.

[43]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[44]  Tao Chen,et al.  GOFFA: Gene Ontology For Functional Analysis – A FDA Gene Ontology Tool for Analysis of Genomic and Proteomic Data , 2006, BMC Bioinformatics.

[45]  E. Thiel,et al.  Prediction of qualitative outcome of oligonucleotide microarray hybridization by measurement of RNA integrity using the 2100 Bioanalyzer™ capillary electrophoresis system , 2009, Annals of Hematology.

[46]  Fred H. Gage,et al.  Wnt signalling regulates adult hippocampal neurogenesis , 2005, Nature.

[47]  A. Takashima,et al.  Direct association of presenilin-1 with beta-catenin. , 1998, FEBS letters.

[48]  Hsien-yu Wang,et al.  Wnt Signaling, Ca2+, and Cyclic GMP: Visualizing Frizzled Functions , 2003, Science.

[49]  T. Friedmann,et al.  Deficiency of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) dysregulates neurogenesis. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  T. Friedmann,et al.  Characterization of the dopamine defect in primary cultures of dopaminergic neurons from hypoxanthine phosphoribosyltransferase knockout mice. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  H. Jinnah,et al.  Role of Neuronal Nitric Oxide in the Dopamine Deficit of HPRT-Deficient Mice , 2007, Metabolic Brain Disease.